臭氧化自体血液疗法联合药物治疗合并症失眠和肌筋膜疼痛综合征:一项前瞻性随机对照研究。

IF 2.5 3区 医学 Q2 CLINICAL NEUROLOGY
Pain Research & Management Pub Date : 2022-11-23 eCollection Date: 2022-01-01 DOI:10.1155/2022/3562191
Wang Shen, Ning Liu, Zhonghua Ji, Hongwei Fang, Feng Liu, Wei Zhang, Xiuqin Yu, Mingxia Wang, Jinyuan Zhang, Xiangrui Wang
{"title":"臭氧化自体血液疗法联合药物治疗合并症失眠和肌筋膜疼痛综合征:一项前瞻性随机对照研究。","authors":"Wang Shen,&nbsp;Ning Liu,&nbsp;Zhonghua Ji,&nbsp;Hongwei Fang,&nbsp;Feng Liu,&nbsp;Wei Zhang,&nbsp;Xiuqin Yu,&nbsp;Mingxia Wang,&nbsp;Jinyuan Zhang,&nbsp;Xiangrui Wang","doi":"10.1155/2022/3562191","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To examine the efficacy and safety of ozonated autohemotherapy (O3-AHT) combined with pharmacological therapy for comorbid insomnia and myofascial pain syndrome (MPS).</p><p><strong>Materials and methods: </strong>One hundred and eighteen patients were randomly divided into two groups: the control group (<i>N</i> = 50) and the O<sub>3</sub>-AHT group (<i>N</i> = 53). Patients in both groups were given the same pharmacological management for three weeks. Patients in the O<sub>3</sub>-AHT group were treated with ozonated autohemotherapy (the concentration of ozone was 20 <i>µ</i>g/ml in the first week, 30 <i>µ</i>g/ml in the second week, and 40 <i>µ</i>g/ml in the third week) combined with pharmacological therapy. Primary (the insomnia severity index (ISI) and visual analogue scale (VAS)) and secondary outcomes (the Epworth sleepiness scale (ESS), polysomnography data, the anxiety and preoccupation about sleep questionnaire (APSQ), the beck depression index (BDI), and the multidimensional fatigue inventory (MFI)) were examined at pretreatment, posttreatment, 1 month, and 6 months.</p><p><strong>Results: </strong>Fifty patients in the control group and fifty-three patients in the O<sub>3</sub>-AHT group completed the study. In both groups, insomnia and pain symptoms were relieved significantly compared with pretreatment. Compared with the control group, the O<sub>3</sub>-AHT group had significantly improved sleep quality, pain, and negative mood at different time points. No adverse complications were observed in either group.</p><p><strong>Conclusion: </strong>Compared with pharmacological therapy alone, ozonated autohemotherapy combined with pharmacological therapy can ameliorate insomnia, reduce pain intensity, improve negative mood, and alleviate fatigue more effectively without serious adverse complications.</p>","PeriodicalId":19913,"journal":{"name":"Pain Research & Management","volume":"2022 ","pages":"3562191"},"PeriodicalIF":2.5000,"publicationDate":"2022-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195166/pdf/","citationCount":"1","resultStr":"{\"title\":\"Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study.\",\"authors\":\"Wang Shen,&nbsp;Ning Liu,&nbsp;Zhonghua Ji,&nbsp;Hongwei Fang,&nbsp;Feng Liu,&nbsp;Wei Zhang,&nbsp;Xiuqin Yu,&nbsp;Mingxia Wang,&nbsp;Jinyuan Zhang,&nbsp;Xiangrui Wang\",\"doi\":\"10.1155/2022/3562191\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To examine the efficacy and safety of ozonated autohemotherapy (O3-AHT) combined with pharmacological therapy for comorbid insomnia and myofascial pain syndrome (MPS).</p><p><strong>Materials and methods: </strong>One hundred and eighteen patients were randomly divided into two groups: the control group (<i>N</i> = 50) and the O<sub>3</sub>-AHT group (<i>N</i> = 53). Patients in both groups were given the same pharmacological management for three weeks. Patients in the O<sub>3</sub>-AHT group were treated with ozonated autohemotherapy (the concentration of ozone was 20 <i>µ</i>g/ml in the first week, 30 <i>µ</i>g/ml in the second week, and 40 <i>µ</i>g/ml in the third week) combined with pharmacological therapy. Primary (the insomnia severity index (ISI) and visual analogue scale (VAS)) and secondary outcomes (the Epworth sleepiness scale (ESS), polysomnography data, the anxiety and preoccupation about sleep questionnaire (APSQ), the beck depression index (BDI), and the multidimensional fatigue inventory (MFI)) were examined at pretreatment, posttreatment, 1 month, and 6 months.</p><p><strong>Results: </strong>Fifty patients in the control group and fifty-three patients in the O<sub>3</sub>-AHT group completed the study. In both groups, insomnia and pain symptoms were relieved significantly compared with pretreatment. Compared with the control group, the O<sub>3</sub>-AHT group had significantly improved sleep quality, pain, and negative mood at different time points. No adverse complications were observed in either group.</p><p><strong>Conclusion: </strong>Compared with pharmacological therapy alone, ozonated autohemotherapy combined with pharmacological therapy can ameliorate insomnia, reduce pain intensity, improve negative mood, and alleviate fatigue more effectively without serious adverse complications.</p>\",\"PeriodicalId\":19913,\"journal\":{\"name\":\"Pain Research & Management\",\"volume\":\"2022 \",\"pages\":\"3562191\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2022-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195166/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pain Research & Management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2022/3562191\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain Research & Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/3562191","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:观察臭氧自血疗法(O3-AHT)联合药物治疗合并失眠和肌筋膜疼痛综合征(MPS)的疗效和安全性。材料和方法:将118例患者随机分为两组:对照组(N = 50)和O3-AHT组(N = 53)。两组患者均接受相同的药物治疗,为期三周。O3-AHT组的患者接受臭氧自血疗法(臭氧浓度为20 第一周为µg/ml,30 第二周为µg/ml,40 第三周为µg/ml)与药物治疗相结合。在治疗前、治疗后、1个月和6个月检查主要结果(失眠严重程度指数(ISI)和视觉模拟量表(VAS))和次要结果(Epworth嗜睡量表(ESS)、多导睡眠图数据、睡眠焦虑和专注问卷(APSQ)、贝克抑郁指数(BDI)和多维疲劳量表(MFI))。结果:对照组50名患者和O3-AHT组53名患者完成了研究。两组患者的失眠和疼痛症状均较治疗前明显减轻。与对照组相比,O3-AHT组在不同时间点的睡眠质量、疼痛和负面情绪均有显著改善。两组均未观察到不良并发症。结论:与单纯药物治疗相比,臭氧自血疗法联合药物治疗能更有效地改善失眠、减轻疼痛强度、改善消极情绪、缓解疲劳,无严重不良并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study.

Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study.

Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study.

Objective: To examine the efficacy and safety of ozonated autohemotherapy (O3-AHT) combined with pharmacological therapy for comorbid insomnia and myofascial pain syndrome (MPS).

Materials and methods: One hundred and eighteen patients were randomly divided into two groups: the control group (N = 50) and the O3-AHT group (N = 53). Patients in both groups were given the same pharmacological management for three weeks. Patients in the O3-AHT group were treated with ozonated autohemotherapy (the concentration of ozone was 20 µg/ml in the first week, 30 µg/ml in the second week, and 40 µg/ml in the third week) combined with pharmacological therapy. Primary (the insomnia severity index (ISI) and visual analogue scale (VAS)) and secondary outcomes (the Epworth sleepiness scale (ESS), polysomnography data, the anxiety and preoccupation about sleep questionnaire (APSQ), the beck depression index (BDI), and the multidimensional fatigue inventory (MFI)) were examined at pretreatment, posttreatment, 1 month, and 6 months.

Results: Fifty patients in the control group and fifty-three patients in the O3-AHT group completed the study. In both groups, insomnia and pain symptoms were relieved significantly compared with pretreatment. Compared with the control group, the O3-AHT group had significantly improved sleep quality, pain, and negative mood at different time points. No adverse complications were observed in either group.

Conclusion: Compared with pharmacological therapy alone, ozonated autohemotherapy combined with pharmacological therapy can ameliorate insomnia, reduce pain intensity, improve negative mood, and alleviate fatigue more effectively without serious adverse complications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pain Research & Management
Pain Research & Management CLINICAL NEUROLOGY-
CiteScore
5.30
自引率
0.00%
发文量
109
审稿时长
>12 weeks
期刊介绍: Pain Research and Management is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of pain management. The most recent Impact Factor for Pain Research and Management is 1.685 according to the 2015 Journal Citation Reports released by Thomson Reuters in 2016.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信